US Patent 8,022,228: Asenapine Maleate Crystal Form, Claim Scope, Expiration and Patent Landscape

US Patent 8,022,228 protects a specific crystalline form of asenapine maleate, the active pharmaceutical ingredient in Saphris sublingual tablets. Its core limitations are the orthorhombic crystal structure, defined X-ray powder diffraction peaks, controlled particle size, and a manufacturing process using a 9:1 ethanol/water crystallization solvent followed by micronization.

The patent does not broadly cover asenapine, asenapine maleate, or every physical form of asenapine maleate. It is a solid-state and process patent directed to a particular pharmaceutical form and its preparation.

What compound does US 8,022,228 protect?

The claimed compound is asenapine maleate, chemically identified as:

trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate

Asenapine is an atypical antipsychotic marketed in the United States as Saphris by Organon and its predecessors. The product is administered as a sublingual tablet for schizophrenia and bipolar I disorder. The patent covers a microcrystalline orthorhombic form of the asenapine maleate salt, not the free base alone.

Patent identification

Item	Data
US patent	8,022,228
Subject	Crystalline form of asenapine maleate
Patent type	Solid-state composition and manufacturing process
Active ingredient	Asenapine maleate
Original commercial product	Saphris sublingual tablets
Original owner lineage	Schering Corporation and related Merck entities
Priority basis	European/PCT family with an earliest claimed priority in 2004
Grant date	September 20, 2011
Principal technology	Orthorhombic microcrystalline asenapine maleate
Key analytical method	CuKα X-ray powder diffraction
Key process	Crystallization from 9:1 ethanol/water, followed by micronization

The exact enforceable term depends on the patent’s complete prosecution history, including patent-term adjustment and any terminal disclaimer. On the disclosed priority chronology, the ordinary US patent term is centered on late 2025, subject to those adjustments. The patent is therefore a late-life or potentially expired patent asset rather than a long-duration blocking patent.

What are the independent and dependent claims in US 8,022,228?

Claim 1 is the principal product claim. Claim 5 is the principal process claim. Claims 2 through 4, 6, and 7 narrow the product claims by particle size or diffraction characteristics.

Claim structure

Claim	Subject matter	Main limitation
1	Product	Orthorhombic microcrystalline asenapine maleate
2	Product	Claim 1 form with d95 of about 100 microns or less
3	Product	Claim 2 form with XRPD peaks at 10.5° and 15.7°
4	Product	Claim 1 form with seven specified XRPD peaks
5	Process	At least 90 wt.% orthorhombic form; 9:1 ethanol/water crystallization; micronization
6	Product	Claim 2 form with d95 of about 50 microns or less
7	Product	Claim 2 form with d95 of about 30 microns or less

Claim 1 is structurally broad within the patent’s subject matter because it does not require a particular particle-size threshold or a complete seven-peak XRPD profile. It does require the compound to be in the microcrystalline orthorhombic form.

Claim 5 is narrower in process terms but may be commercially significant because a generic manufacturer could produce the same claimed crystal form through a different crystallization and particle-engineering route.

How broad is claim 1?

Claim 1 covers asenapine maleate when it exists in the specified microcrystalline orthorhombic crystal form. The claim is not limited by:

a particular tablet strength;
a particular sublingual excipient system;
a particular dosage regimen;
a particular therapeutic indication;
a specific manufacturing scale;
a stated particle-size cutoff;
the full seven-peak XRPD pattern in claim 4.

The central dispute in an infringement case would be whether the accused material is the claimed orthorhombic microcrystalline form. The chemical identity alone is insufficient. A product containing asenapine maleate in a different polymorph, amorphous form, solvate, or physical form would not necessarily fall within claim 1.

The term “microcrystalline” and the characterization of the orthorhombic form would likely be interpreted using the patent specification, XRPD data, particle morphology, and relevant pharmaceutical solid-state evidence. The words “about” in the particle-size claims create ordinary measurement tolerance, but they do not eliminate the need to establish the claimed d95 threshold.

What do the XRPD claims protect?

Claims 3 and 4 use XRPD peak positions to define the crystal form.

Claim 3 requires peaks at approximately:

10.5° 2θ; and
15.7° 2θ.

Claim 4 identifies a more extensive pattern:

10.5°;
15.7°;
18.3°;
19.0°;
22.2°;
23.2°; and
27.5° 2θ.

The XRPD claims are analytical product claims. They do not merely protect a test method. They define the physical form of the asenapine maleate material by its diffraction profile.

The practical infringement question is whether the accused active pharmaceutical ingredient produces the claimed peaks under materially comparable testing conditions. Differences in instrument configuration, sample preparation, radiation source, peak resolution, and polymorph content can affect the analysis. A complete comparison would normally examine the raw diffractogram rather than isolated peak labels.

Relative scope of the XRPD claims

Claim 3 is narrower than claim 2 because it adds two diffraction peaks. Claim 4 is narrower in analytical definition because it identifies seven peaks, although it depends directly on claim 1 rather than claim 3. A material could potentially satisfy claim 4 without satisfying claim 3 only if claim-dependency or drafting interpretation produced an unusual result; as written, the seven-peak form includes the two peaks recited in claim 3.

What particle sizes are protected?

The patent claims three particle-size thresholds:

Claim	d95 threshold
2	About 100 microns or less
6	About 50 microns or less
7	About 30 microns or less

The d95 value means that approximately 95% of the measured particle population is at or below the specified particle size, subject to the measurement method and “about” language.

The narrower 50-micron and 30-micron claims may be particularly relevant to sublingual dosage-form performance. Particle size can affect blending, content uniformity, dissolution, mouthfeel, and dose delivery. A generic manufacturer may avoid these claims by using a larger particle distribution, but that approach could affect product performance and regulatory comparability.

A particle-size design-around would need to consider whether the product still falls within claim 1 or claim 4. Claims 6 and 7 are dependent claims and do not define the entire patent scope.

What process does claim 5 protect?

Claim 5 requires a process with four material features:

The product is the orthorhombic microcrystalline form of asenapine maleate.
The orthorhombic form constitutes at least about 90 wt.% of the compound.
Crystallization occurs from an ethanol/water mixture in a 9:1 volume proportion.
The resulting crystalline material is micronized.

This claim is narrower than the product claims because it requires a defined solvent ratio and a micronization step. A manufacturer that obtains the same crystal form through a different solvent system, antisolvent process, temperature profile, seeding strategy, or particle-reduction technique may avoid literal infringement of claim 5. That alternative process would remain exposed to the product claims if the resulting active ingredient meets claim 1, 3, or 4.

The 90 wt.% limitation also creates a purity and phase-composition issue. The relevant question is whether the final crystalline material contains at least approximately 90 wt.% of the claimed orthorhombic form, not merely whether the process was intended to produce that form.

When does US Patent 8,022,228 lose exclusivity?

The ordinary patent term is based on the earliest effective nonprovisional or PCT filing date, not the September 2011 grant date. Based on the patent family’s 2004 priority chronology, the ordinary term is expected to fall in late 2025, subject to patent-term adjustment, terminal disclaimer, or other prosecution-specific changes.

The patent should be distinguished from FDA regulatory exclusivity:

Protection	Relevance to asenapine
New chemical entity exclusivity	Applied to the original Saphris approval and expired years before the expected patent expiration
Pediatric exclusivity	Could extend certain FDA-listed protections by six months if granted
Underlying compound patent	Covered asenapine itself and had a different expiration history
Formulation patents	Could cover sublingual delivery or excipient systems
US 8,022,228	Covers the orthorhombic microcrystalline maleate form and process

Patent expiry does not automatically establish FDA approval eligibility. A generic applicant must still satisfy the ANDA requirements and address any listed patents through certification or a regulatory pathway permitted by the Orange Book.

What is the Orange Book status of US 8,022,228?

The Orange Book lists patents associated with approved drug products when the sponsor identifies them under FDA patent-listing rules. For Saphris, the relevant patent landscape has included:

the asenapine compound patent;
formulation or dosage-form patents;
patents directed to the crystalline asenapine maleate form.

US 8,022,228 is relevant to the Saphris patent estate because it claims the solid form used in the commercial product. Its commercial significance depends on whether it was listed for the relevant NDA, whether the listing remained active during the generic filing period, and whether any patent-term adjustment or pediatric extension applied.

An Orange Book listing does not itself establish validity or infringement. It gives an ANDA applicant a statutory patent-certification issue and can trigger the Hatch-Waxman litigation framework.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. For US 8,022,228, a generic applicant could target several vulnerability points:

Product-form noninfringement

The applicant could argue that its asenapine maleate is not the claimed orthorhombic microcrystalline form. Possible distinctions include:

a different polymorph;
an amorphous or partially amorphous material;
a solvate or hydrate;
a crystal mixture below the claimed form threshold;
a particle distribution outside the dependent claims.

Process noninfringement

A manufacturer could avoid claim 5 by not using the specified 9:1 ethanol/water mixture or by omitting the claimed micronization sequence. This defense does not defeat a product claim if the final material falls within the claimed crystal form.

Anticipation and obviousness

Validity challenges would focus on prior art disclosing:

asenapine maleate;
crystalline salts of asenapine;
orthorhombic crystal forms;
XRPD peaks corresponding to the claimed form;
particle-size reduction for sublingual delivery;
ethanol/water crystallization and micronization.

Solid-form patents often depend on whether the specific polymorph was disclosed or whether its properties were predictable from earlier salt and crystallization disclosures. Evidence of unexpected stability, dissolution, manufacturability, or bioavailability can support nonobviousness, but the patent’s strength depends on the prosecution record and prior-art disclosures.

Enablement and written description

The claims are technically specific, which generally supports written-description and enablement arguments. The principal issue would be whether the specification adequately teaches the claimed orthorhombic form across the full scope of the product claims and whether the analytical and particle-size definitions are reproducible.

How strong is the patent estate for Saphris?

The estate is strongest where the commercial product contains the claimed orthorhombic microcrystalline form and the generic applicant uses a substantially identical active ingredient. It is weaker as a standalone barrier if:

the patent term has expired;
the product is not currently listed;
the generic can use a noninfringing polymorph;
the generic’s process avoids the 9:1 solvent ratio;
earlier prior art discloses the same crystal form;
the product can be characterized without relying on the claimed particle-size limitations.

The patent is narrower than a compound patent but potentially more difficult to design around than a formulation patent because the active pharmaceutical ingredient itself may be the claimed subject matter.

How does US 8,022,228 compare with other asenapine patents?

Patent category	Protected subject matter	Design-around potential
Compound patent	Asenapine molecule or salt	Low if broadly claimed, but term likely expired or near expiry
Crystal-form patent	Orthorhombic microcrystalline asenapine maleate	Moderate through polymorph or physical-form selection
Formulation patent	Sublingual tablet composition and excipients	Moderate to high through formulation redesign
Method-of-use patent	Treatment of schizophrenia or bipolar disorder	Depends on labeling and induced-infringement facts
Manufacturing patent	Solvent system, crystallization, micronization	Usually higher through process substitution

US 8,022,228 is not principally a method-of-use patent. It does not claim treatment of a disease, a dosing regimen, or a patient population. Its commercial value derives from control of the active ingredient’s physical form.

What generic launch scenarios exist?

A generic asenapine applicant would likely evaluate four pathways:

Wait for patent expiry. This minimizes litigation risk but delays market entry.
File a Paragraph IV certification. This can support an earlier launch but exposes the applicant to Hatch-Waxman litigation and a possible 30-month stay.
Use a different solid form. This creates a product-form noninfringement position but requires adequate pharmaceutical development and regulatory support.
Use the same product form with a different process. This may avoid claim 5 but remains exposed to claims 1, 3, and 4.

For a sublingual product, a different crystal form may affect dissolution, taste, stability, and dose uniformity. The ability to design around the patent therefore depends on both patent law and product-development constraints.

What manufacturing and geographic barriers remain?

The patent is a US right. It does not directly prevent manufacture, sale, or use outside the United States. Geographic exposure depends on corresponding foreign family members and their status in each jurisdiction.

Relevant jurisdictions include:

United States;
European Patent Convention states;
Canada;
Japan;
other countries designated in the PCT application.

A manufacturer outside the United States may still face US liability if it exports the claimed active ingredient for sale or use in the United States. US law also provides potential exposure for importing a patented product and, in certain circumstances, supplying components for a patented process.

The manufacturing barrier is strongest when the commercial supply chain uses the claimed orthorhombic form regardless of the production route. It is weaker when a supplier can deliver a different form that meets regulatory and performance requirements.

What is the commercial exposure from the patent?

Saphris sales were concentrated in the branded product before generic competition. The relevant exposure is the portion of asenapine revenue attributable to US sales of products using the patented crystal form. A form patent can protect the commercial product even when the underlying compound patent has expired, but its economic value falls sharply after patent expiry or successful generic design-around.

The key commercial variables are:

current US Saphris and generic sales;
the number of approved generic applicants;
whether generics use the same active form;
the expiration status of all Orange Book-listed patents;
settlement restrictions, if any;
payer substitution and formulary behavior;
manufacturing cost differences between crystal forms.

No separate royalty or licensing arrangement is established by the claim text alone. Any license, assignment, covenant not to sue, or settlement agreement would require review of the patent assignment records, SEC disclosures, court docket, and FDA listing history.

Key Takeaways

US 8,022,228 is a solid-form patent for orthorhombic microcrystalline asenapine maleate.
Claim 1 is the central product claim; claim 5 is the principal process claim.
Claims 2, 6, and 7 narrow the invention by d95 particle-size thresholds of about 100, 50, and 30 microns.
Claims 3 and 4 define the form through CuKα XRPD peaks.
A different manufacturing process may avoid claim 5 but not the product claims.
A different polymorph or noncrystalline form may provide a product-form design-around.
The patent’s ordinary term is centered on late 2025 based on the disclosed priority chronology, subject to patent-term adjustment and related statutory extensions.
The patent does not claim asenapine broadly, a therapeutic indication, or every sublingual formulation.
Generic risk depends on the current Orange Book listing, patent term, solid-form characterization, and the ANDA applicant’s Paragraph IV strategy.
The patent’s economic value is materially lower after expiry unless related formulation, method-of-use, or manufacturing patents remain enforceable.

FAQs About US Patent 8,022,228

Is US 8,022,228 a patent on Saphris itself?

No. It is a patent on a particular orthorhombic microcrystalline form of asenapine maleate and a process for producing it. Other patents covered the asenapine compound, formulations, or related uses.

Can a generic avoid US 8,022,228 by using a different particle size?

Only partially. A particle size above the thresholds in claims 2, 6, and 7 may avoid those dependent claims. It may still infringe claim 1 or claim 4 if the material remains the claimed orthorhombic form.

Does using a different solvent avoid the patent?

It may avoid process claim 5 if the process does not use the claimed 9:1 ethanol/water crystallization step. It does not necessarily avoid the product claims if the resulting active ingredient has the claimed orthorhombic microcrystalline form.

Is an XRPD match alone enough to establish infringement?

XRPD evidence is central for claims 3 and 4, but infringement analysis also requires evaluation of the full claim language, testing conditions, crystal form, particle-size limitations, and applicable claim-construction principles.

Does patent expiry eliminate all generic barriers to asenapine?

No. FDA approval requirements, other listed patents, formulation patents, regulatory exclusivity, supply arrangements, and product-development requirements can remain relevant after this patent expires.

References

United States Patent and Trademark Office. (2011). U.S. Patent No. 8,022,228, crystalline form of asenapine maleate.
U.S. Food and Drug Administration. (2009). Saphris (asenapine maleate) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations [Orange Book].
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
World Intellectual Property Organization. (2005). Patent Cooperation Treaty publication relating to crystalline forms of asenapine maleate.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-003	Mar 12, 2015	AB	RX	Yes	No	8,022,228*PED	⤷ Start Trial			Y		⤷ Start Trial
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-001	Aug 13, 2009	AB	RX	Yes	No	8,022,228*PED	⤷ Start Trial			Y		⤷ Start Trial
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-002	Aug 13, 2009	AB	RX	Yes	Yes	8,022,228*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 8,022,228

Which drugs does patent 8,022,228 protect, and when does it expire?

Summary for Patent: 8,022,228